Q3 EPS Estimate for Inovio Pharmaceuticals Raised by Analyst
HC Wainwright has increased its Q3 2026 EPS estimate for Inovio Pharmaceuticals (NASDAQ:INO) to a loss of $0.20 per share, up from a previous estimate of $0.24, while maintaining a "Neutral" rating. Analyst sentiment for Inovio is generally positive, with a consensus "Moderate Buy" …